Read + Share
. Correction to: "Cardiovascular Benefits of Empagliflozin Are Associated With Gut
Microbiota and Plasma Metabolites in Type 2 Diabetes". J Clin Endocrinol Metab 2022 Sep 14. pii: 6698734. doi: 10.1210.
PMID: 36104307
|
 |
|
. Correction to: "Cardiovascular Benefits of Empagliflozin Are Associated With Gut
Microbiota and Plasma Metabolites in Type 2 Diabetes". J Clin Endocrinol Metab 2022 Sep 14. pii: 6698734. doi: 10.1210.
PMID: 36104307
|
|
|
|